ENGNW shows severe financial deterioration with R&D expenses increasing 147% to $94.5M, net losses doubling to $117.3M, and cash burning down 71% to $50.2M while outstanding shares increased 31% indicating significant dilution.
The company is experiencing rapid cash burn with operating cash flow losses doubling to $99.2M while cash reserves have dropped dramatically from $173M to $50.2M, raising concerns about runway and potential need for additional financing. The 31% increase in outstanding shares from 51M to 67M suggests recent equity dilution, while the massive R&D spending increase indicates aggressive investment in their clinical programs that may not be sustainable at current cash levels.
The financial picture shows a company in aggressive expansion mode with unsustainable burn rates - R&D expenses nearly doubled to $94.5M driving net losses to $117.3M, while operating cash outflows more than doubled to $99.2M. Cash reserves plummeted 71% to just $50.2M despite a 31% increase in share count suggesting recent equity raises, indicating potential liquidity concerns. The combination of accelerating losses, depleting cash, and recent dilution signals significant financial stress for this clinical-stage biotech company.
Interest expense surged 248.1% — significant debt increase or rising rates materially impacting earnings.
R&D investment increased 146.6% — signals commitment to future product development, though near-term margin impact.
Current liabilities surged 118.1% — significant near-term obligations; verify ability to meet short-term debt.
Net income declined 112.7% — review whether driven by operations, interest costs, or non-recurring items.
Operating cash flow fell 105.5% — earnings quality concerns; investigate working capital changes and non-cash items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Cash declined 71% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Capital expenditure jumped 60.5% — major investment cycle underway; assess returns on deployment.
Liabilities grew 39.4% — significant increase in debt or obligations, assess impact on financial flexibility.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →